Topiramate therapy for paroxysmal kinesigenic choreoathetosis.

Abstract

We observed the clinical efficacy of topiramate for paroxysmal kinesigenic choreoathetosis (PKC). Topiramate was administered as a monotherapy with titrated dosages to 8 patients with PKC. Target daily dose of topiramate was 100 to 200 mg; the follow-up period ranged from 8 months to 2 years. All of the patients became attack-free, and side effects were mild. The results show that topiramate is effective as a monotherapy for treating patients with PKC. The response to topiramate indicates that the disease may be caused by an ion channel defect.

• Authors: Yuan-Gui Huang, Yun-Chun Chen, Fang Du, Rui Li, Ge-Lin Xu, Wen Jiang, Jing Huang
• Journal: Movement disorders : official journal of the Movement Disorder Society (Mov Disord) Vol. 20 Issue 1 Pg. 75-7 (Jan 2005) ISSN: 0885-3185 [Print] United States
• PMID: 15390133 (Publication Type: Clinical Trial, Comparative Study, Journal Article)
• Copyright: (c) 2004 Movement Disorder Society.

Chemical References

• Anticonvulsants
• Topiramate
• Fructose

Topics

• Adolescent
• Adult
• Anticonvulsants (therapeutic use)
• Athetosis (complications, drug therapy)
• Child
• Chorea (complications, drug therapy)
• Dose-Response Relationship, Drug
• Female
• Follow-Up Studies
• Fructose (analogs & derivatives, therapeutic use)
• Humans
• Male
• Topiramate
• Treatment Outcome